BioSpace News Archive

DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings

The Personalized Medicine Coalition (PMC) will convene its 14th Annual Personalized Medicine Conference at Harvard Medical School from November 14 – 15, 2018, to address unresolved challenges in health care that FDA Commissioner Scott Gottlieb, M.D., warns may discourage the development of “potentially curative” treatment strategies.

The Government of Canada recognizes that Canadian innovation has helped make our country a leader in producing safe, high quality products and we are committed to fostering innovation in the agricultural sector – here in Canada and beyond.

Quadrant Biosciences announced today that they will support Autism Speaks’ mission with funding to expand delivery of reliable information, resources and support through the Autism Speaks Autism Response Team.

Today, the U.S. Food and Drug Administration and the Department of Defense’s (DoD) Office of Health Affairs signed a Memorandum of Understanding regarding medical product development and assessment.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its third quarter 2018 financial results.

Janssen Pharmaceuticals, Inc. has initiated a voluntary recall of one lot of ORTHO-NOVUM® 1/35 (norethindrone/ethinyl estradiol) Tablets and two lots of ORTHO-NOVUM® 7/7/7 (norethindrone/ethinyl estradiol) Tablets to the pharmacy level.

Doug and Leah Mickschl are using the power of creativity and love to find a cure for type 1 diabetes.

Sage Therapeutics (NASDAQ: SAGE) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) jointly voted (17 yes, 1 no) that data support the favorable benefit-risk profile of ZULRESSO

Heavy Hitters, the original best-tasting vape cartridge with the most enjoyable high from Southern California, is looking for 20 Original, Raw, Uncompromising, Authentic people to smoke weed, travel, attend high-profile events and – most importantly – get paid as part of the company’s “The Originals” ambassador program.